Head-To-Head Survey: Nephros (NASDAQ:NEPH) & Hero Technologies (OTCMKTS:HENC)

Hero Technologies (OTCMKTS:HENC) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and price targets for Hero Technologies and Nephros, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hero Technologies	0	0	0	0	0.00
Nephros	0	1	1	0	2.50

Nephros has a consensus price target of $6.00, suggesting a potential upside of 107.61%. Given Nephros’ stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than Hero Technologies.

Risk and Volatility

Hero Technologies has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Nephros has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Insider and Institutional Ownership

41.1% of Nephros shares are owned by institutional investors. 0.2% of Hero Technologies shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Hero Technologies and Nephros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hero Technologies	N/A	N/A	N/A
Nephros	6.35%	12.22%	9.38%

Valuation & Earnings

This table compares Hero Technologies and Nephros”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hero Technologies	N/A	N/A	N/A	N/A	N/A
Nephros	$18.79 million	1.64	$1.19 million	$0.11	26.27

Nephros has higher revenue and earnings than Hero Technologies.

Summary

Nephros beats Hero Technologies on 10 of the 10 factors compared between the two stocks.

About Hero Technologies

Hero Technologies Inc. operates as an early-stage cannabis company. It focuses on the provision of BlackBox, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and the cultivation of large flowering plants and create increased harvest efficiencies. The company also intends to offer cannabis genetic engineering farmland for medical and recreational cannabis cultivation, production, distribution, packaging, and retail operations, as well as for dispensaries. The company is based in Dover, Delaware.

About Nephros

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.